A study initiated by Chr. Hansen has shown that bifidobacteria and lactobacilli are present in breast milk from Chinese mothers, strengthening the case for adding clinically documented probiotics to infant formula, in order to improve nutrition.
In the last decade, research has shown that breast milk from Western women contains bacteria, such as bifidobacteria and lactobacilli. Bifidobacteria are known to play an important role in the development of a healthy microbiota in infants and children, which is beneficial to the digestive and immune functions. A new study now confirms a presence of the same bacteria in breast milk from Chinese mothers.
The study was initiated by Chr. Hansen and conducted in collaboration with Shanghai Institute of Pediatric Research. The main author, Dr. Linxi Qian, presented the results last week at the European Society for Pediatric Gastroenterology, Hepatology and Nutrition 2015, in Amsterdam.
Important findings for infant formula development
Chr. Hansen continuously invests in clinical studies within the infant segment, and previous studies have shown that the probiotic Bifidobacterium strain named BB-12® may be effective in preventing gastrointestinal and respiratory infections in infants and children. The product portfolio also includes Lactobacillus,LGG® which is the world’s best documented lactobacillus.
Mikkel Jungersen, Scientific Advisor, Human Health & Nutrition, Chr. Hansen, says: “The confirmed presence of bifidobacteria and lactobacilli in Chinese breast milk is essential knowledge for all those who are active in the infant formula business in China. It makes sense for a mother who is feeding her baby with infant formula to prefer a product resembling real breast milk the most, and this study shows that bifidobacteria and/or lactobacilli are essential additives to nutritious infant formula.”
Note: Chr. Hansen is committed to the highest standards of responsible marketing of breast milk substitutes and complies with the WHO Code as implemented by national governments.
Chouraqui et al. 2004; Saavedra et al. 2004; Saavedra et al. 1994; Taipale et al. 2010 Rautava et al. 2009.
Chr. Hansen is a leading, global bioscience company that develops natural ingredient solutions for the food, nutritional, pharmaceutical and agricultural industries. We develop and produce cultures, enzymes, probiotics and natural colors for a rich variety of foods, confectionery, beverages, dietary supplements and even animal feed and plant protection. Our product innovation is based on more than 30,000 microbial strains – we like to refer to them as ‘good bacteria’. Our solutions enable food manufacturers to produce more with less – while also reducing the use of chemicals and other synthetic additives – which make our products highly relevant in today’s world. We have been delivering value to our partners – and, ultimately, end consumers worldwide – for over 140 years. We are proud that more than one billion people consume products containing our natural ingredients every day. Revenue in the 2017/18 financial year was EUR 1,097 million. Chr. Hansen was founded in 1874 and is listed on Nasdaq Copenhagen.